Navigation Links
Rigel Announces Second Quarter 2011 Financial Results
Date:8/2/2011

rug application with respect to fostamatinib. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "may," "intend," "believe," "plan." "expect," "potential," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks associated with Rigel's need for additional capital, the timing and success of preclinical studies and clinical trials and the potential problems that may arise in the research and development and approval process, as well as other risks detailed from time to time in Rigel's reports with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2011. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Contact: Ryan D. Maynard
Phone: 650.624.1284
Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
Phone: 650.430.3777
Email: susan@alchemyemail.comSTATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months Ended June 30,Six Months Ended June 30,2011201020112010(unaudited)Revenues:Contract revenues

$
395

$
49,457$
395

$ 52,718Operating expenses:Research and development (see Note A)

17,109

16,81532,215

34,240General and administrative (see Note A)

4,843

5,66410,597

13,850Total operat
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rigel to Host Update Conference Call
2. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
3. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
4. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
5. Rigel to Participate at the RBC Capital Markets Healthcare Conference
6. Rigel to Present at Citis Biotech Day
7. Rigel Announces First Quarter 2009 Financial Results
8. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
9. Rigel Earns Milestone Payments From AstraZeneca
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
11. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... GLOBAL MARKETS , that the global market RNA interference ... nearly $38.8 billion by 2018, with a five-year compound ... category, the fastest moving segment of the market, is ... of RNAi therapeutics has shown tremendous growth and has ...
(Date:8/1/2014)... Aug. 1, 2014 Glencoe Software, ... of "Data InPress" ( http://glencoesoftware.com/data-inpress.html ), a ... multidimensional image data into on-line publications.  The ... Video Injection Service. Photo - ... http://photos.prnewswire.com/prnh/20140731/132409 The DataViewer ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Food ... are increasingly searching for food alternatives that offer ... benefits. The food ingredient market has numerous players ... such as Vital Force Technology (VFT). VFT ... than 4,000 energetic patterns, all tested to produce ...
(Date:7/31/2014)... , the leading life sciences employment and news website, launched the ... Illinois , Indiana , ... , Minnesota , Missouri , ... Wisconsin . BioMidwest is a leader in biotech and ... in this region in 2013. The life sciences sector in this area ...
Breaking Biology Technology:Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Midwest Biotech Leaders Featured On BioSpace Map 2
... To validate any RNAi experiment, target mRNA , ... using a positive control siRNA that is known to be effective, , ... , Validation is also necessary ... effectiveness and potency of any siRNA sequence. Finally, , ...
... Microarrays , ... engineered to maximize yields of full-length cDNA , ... 100 ng of input RNA in a single round for GeneChip , ... cRNA synthesis powered by , MEGAscript, the best ...
... Total RNA Isolation from Formalin Fixed Paraffin Embedded (FFPE) Tissues , ... Phenol-free isolation of total RNA from , FFPE tissues , ... href="http://www.ambiondx.com/products/optimum/index.html">Optimum , ... and rapid protocol , for ...
Cached Biology Technology:Confirming RNAi Effects Is Now Easier Than Ever 2Confirming RNAi Effects Is Now Easier Than Ever 3Confirming RNAi Effects Is Now Easier Than Ever 4Confirming RNAi Effects Is Now Easier Than Ever 5Improving RNA Amplification 2Improving RNA Amplification 3Improving RNA Amplification 4Improving RNA Amplification 5Improving RNA Amplification 6Improving RNA Amplification 7Improving RNA Amplification 8Improving RNA Amplification 9Improving RNA Amplification 10Improving RNA Amplification 11Improving RNA Amplification 12Improving RNA Amplification 13Improving RNA Amplification 14Optimum FFPE RNA Isolation Kit 2Optimum FFPE RNA Isolation Kit 3Optimum FFPE RNA Isolation Kit 4
(Date:7/31/2014)... protected 100 percent of animal models against the highly ... causes an intestinal disease that kills approximately 30,000 Americans ... Infection and Immunity . , In the ... against the purified toxins produced by C. difficile ... a laboratory model that mimics the human disease, after ...
(Date:7/31/2014)... better identify and treat those with fibromuscular dysplasia (FMD). ... sized arteries in the body, which can restrict blood flow ... new report appearing in August 2014 issue of ... FMD may not be limited to the arteries as currently ... bones and joints, as well as evidence that inflammation may ...
(Date:7/31/2014)... they are an iconic symbol of tropical resorts ... landscape. Some, like Hawaii,s State Flower- Hibiscus ... relatively few botanists and Hawaiian conservation workers, however, ... related group of plants known as Hibiscadelphus ... Hibiscus species are in fact highly endangered. Until ...
Breaking Biology News(10 mins):C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2Brother of Hibiscus is found alive and well on Maui 2
... developed a slow-release anesthetic drug-delivery system that could ... surgery, and may also have a large impact ... used specially designed fat-based particles called liposomes to ... local anesthesia in rats without apparent toxicity to ...
... Climate change will cause some of Australia,s potential weeds to ... by scientists at CSIRO,s Climate Adaptation Flagship. Weeds cost ... or lost production and cause serious damage to the environment. ... GREENHOUSE 09 conference on climate change, CSIRO researcher, Dr John ...
... Fast food and soft drinks may be making children fatter ... tackling childhood obesity, by reducing children,s consumption of unhealthy food ... also actively seek to keep children happy in other ways, ... Professor Rodolfo Nayga from the University of Arkansas in the ...
Cached Biology News:Long-lasting nerve block could change pain management 2Climate change may wake up 'sleeper' weeds 2Eat, drink and be merry? 2
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Validated and Silencer Pre-designed siRNAs, ...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Biology Products: